耐多药结核病发生耐药的危险因素分析
Analysis of Risk Factors of Drug Resistance in Multidrug-Resistant Tuberculosis
DOI: 10.12677/ACM.2023.13112540, PDF, HTML, XML, 下载: 124  浏览: 7,011  科研立项经费支持
作者: 王艺燃*:大理大学公共卫生学院,云南 大理;云南省传染病医院感染科,云南 昆明;张云桂#, 张红燕, 杨丹丹, 杨雪娟:云南省传染病医院感染科,云南 昆明
关键词: 耐多药结核病耐药危险因素MDR-TB Drug Resistance Risk Factors
摘要: 目的:探讨耐多药结核病患者发生耐药的危险因素,为针对性预防和控制耐多药结核病提供思路。方法:基于云南省传染病医院开展了一项非匹配病例对照研究。将54例耐多药结核病患者作为病例组,52例非耐多药结核病患者作为对照组,收集两组患者的人口学资料(性别、年龄、职业、户籍地)、临床资料(合并糖尿病和既往结核病治疗史)和影像学检查资料(胸部CT有无空洞),并对其进行单因素χ2检验和多因素logistic回归分析,研究结核病患者产生耐药性的危险因素。结果:单因素分析结果表明,既往结核病治疗史与耐多药结核病的发生有关(χ2 = 20.56, P < 0.05),而性别、年龄、职业、户籍地、糖尿病以及胸部CT空洞有无与耐多药结核病的发生无显著相关性(χ2 = 0.31, 1.41, 0.43, 0.05, 3.73, 1.33, P > 0.05);多因素二元Logistic回归分析显示,既往结核病治疗史(OR = 9.173, 95%CI = 3.632~22.985)和合并糖尿病(OR = 9.484, 95%CI = 1.742~51.618)是耐多药结核病发生的独立危险因素。结论:应规范结核病的诊疗,重视结核病合并糖尿病患者结核耐药筛查,早期发现耐药,减少耐药的发生。
Abstract: Objective: To explore the risk factors of resistance in MDR-TB patients, and to provide ideas for tar-geted prevention and control of MDR-TB. Methods: An unmatched case-control study was conducted in Yunnan Provincial Infectious Disease Hospital. 54 multidrug-resistant tuberculosis patients were taken as the case group and 52 non-multidrug-resistant tuberculosis patients as the control group. The demographic data (sex, age, occupation, place of residence), clinical data (diabetes and previous tuberculosis treatment history)and imaging data (whether there are cavities in chest CT) were col-lected from the two groups of patients, and univariate χ2 test and multivariate logistic regression analysis were performed to study the risk factors for drug resistance in tuberculosis patients. Re-sults: The results of univariate analysis showed that previous TB treatment history was associated with the occurrence of MDR-TB (χ2 = 20.56, P < 0.05), while gender, age, occupation, place of resi-dence, diabetes mellitus and chest CT cavities were not significantly associated with the occurrence of MDR-TB (χ2 = 0.31, 1.41, 0.43, 0.05, 3.73, 1.33, P > 0.05), while multivariate binary logistic re-gression analysis showed that previous TB treatment history (OR = 9.173, 95%CI = 3.632~22.985) and diabetes mellitus (OR = 9.484, 95%CI = 1.742~51.618) were independent risk factors for the development of MDR-TB. Conclusion: The diagnosis and treatment of tuberculosis should be stand-ardized, and attention should be paid to the screening of tuberculosis drug resistance in patients with tuberculosis and diabetes, so as to detect drug resistance early and reduce the occurrence of drug resistance.
文章引用:王艺燃, 张云桂, 张红燕, 杨丹丹, 杨雪娟. 耐多药结核病发生耐药的危险因素分析[J]. 临床医学进展, 2023, 13(11): 18094-18100. https://doi.org/10.12677/ACM.2023.13112540

1. 引言

结核病(tuberculosis, TB)作为世界第二位单一传染源引起死亡的疾病尚未消除,仍是世界重点防控的传染病之一。且随着耐药结核病的出现,特别是耐多药结核病(Multidrug-Resistant TB, MDR-TB)的出现,即患者感染的结核分枝杆菌至少对两种一线抗结核药物利福平和异烟肼同时耐药,为结核病的控制和管理带来了新的挑战 [1] 。我国作为全球MDR-TB高负担国家之一,防控形势不容乐观。据世界卫生组织(World Health Organization, WHO)报告显示,2021年我国MDR-TB新发病例数约为3.3万(7.3%),高居世界第四 [2] 。

云南省作为结核病高负担省份之一,承担着结核防控的重任,为了减轻结核病防控压力,探索MDR-TB发生耐药的危险因素以预防MDR-TB很有必要。本研究采用非匹配病例对照研究,利用电子病历系统收集MDR-TB患者与非MDR-TB患者的相关资料,对其进行单因素和多因素分析拟探讨MDR-TB产生的危险因素,为制定有针对性的MDR-TB预防和控制措施提供思路。

2. 资料与方法

2.1. 研究对象

选取云南省传染病医院2020年8月至2022年11月期间住院行抗结核治疗的MDR-TB患者为病例组,选取同医院同期抗结核治疗的非MDR-TB患者为对照组。

2.2. 纳入/排除标准

病例组:痰培养阳性且菌种鉴定为结核分枝杆菌,药敏试验证实对利福平和异烟肼均耐药的患者;对照组:痰结核分枝杆菌检查阳性,药敏试验结果对异烟肼和利福平均敏感的患者。排除标准:病例组和对照组中药敏试验结果证据缺乏的患者将被剔除。

2.3. 资料收集

查阅相关文献找出可能影响耐多药结核发生耐药的因素,使用预先测试和结构化的数据表从电子病历系统中收集数据。收集的影响因素主要包括如下几个方面,1) 患者的人口学资料:如诊断年龄、性别、职业和户籍地;2) 临床特征:合并糖尿病、既往结核病治疗史;3) 影像学检查:肺部CT有无空洞。数据收集和整理由通过培训的两名公共卫生专业研究生完成。并由从事耐药结核病工作的主管医生反复多次核对信息以保证数据的真实性和完整性。

2.4. 统计学分析

选择SPSS软件版本25.0 (IBM公司,美国纽约)进行数据统计分析。定量资料采用均数 ± 标准差(x ± s)表示,无序分类变量资料则采用频数、百分比表示。单因素分析,采用皮尔逊卡方检验(Pearson’s chi-square test)或费舍尔精确检验(Fisher’s exact test)。二元logistic回归用于检验在单因素分析中P < 0.1的自变量与因变量的关系,计算OR值以及95%置信区间。检验水准α = 0.05。危险因素赋值方式如表1所示。

Table 1. Assignment of risk factors for multidrug resistant tuberculosis

表1. 耐多药结核病的危险因素赋值

3. 结果

3.1. 社会人口学特征

根据纳排标准,此次研究共有106例患者被纳入之中,其中病例组MDR-TB患者54例,对照组非MDR-TB患者52例。所有患者年龄为14至78岁,平均年龄为44.56 ± 16.36岁;病例组平均年龄为46.46 ± 15.07岁;对照组平均年龄为42.58 ± 17.52岁。病例组男40人(74.1%),女14 (25.9%)人;对照组男36人(69.2%),女16 (30.8%)人,两组均男性多于女性。此外,病例组和对照组从事职业以农民占比最高,均占比87%。户籍地多在农村,其中病例组有47 (87%)人,对照组46 (86.5%)人。

3.2. MDR-TB发生耐药的单因素分析

将是否发生MDR-TB作为自变量,收集的可疑变量作为自变量,先进行单因素分析,结果如表2所示。单因素分析结果表示,患者有既往结核病治疗史与MDR-TB的发生有关(χ2 = 20.56, P < 0.05),而患者的人口学资料(性别、年龄、职业、户籍地)、合并糖尿病以及胸部CT空洞有无与MDR-TB的发生无相关性(χ2 = 0.31, 1.41, 0.43, 0.05, 3.73, 1.33, P > 0.05)。

Table 2. Single factor analysis of risk factors for multidrug-resistant tuberculosis

表2. 耐多药结核病危险因素的单因素分析

3.3. MDR-TB发生耐药的多因素分析

将单因素分析中P值小于0.1的变量,即合并糖尿病和既往结核病治疗史纳入MDR-TB危险因素多因素分析,结果如表3所示。即患者有既往结核病治疗史以及合并糖尿病是MDR-TB发生的独立危险因素。甚至有糖尿病基础的患者患MDR-TB的风险是不合并糖尿病患者的9倍(OR = 9.484, 95%CI = 1.742~51.618);既往有抗结核治疗史的患者相对于新患者来说更容易患MDR-TB (OR = 9.173, 95%CI = 3.632~22.985)。

Table 3. Multi-factor analysis of risk factors for multidrug-resistant tuberculosis

表3. 耐多药结核病危险因素的多因素分析

4. 讨论

MDR-TB的蔓延,是全球公共卫生所面临最大的挑战之一。据2022年世界卫生组织全球结核病报告显示,全球耐药结核病的负担有所增加,2021年MDR-TB新发病例在2020年的基础上增加了1.3万例,达到45万例。在这45万例患者中,仅有1/3需要治疗的患者得到了治疗 [2] 。且MDR-TB由于治疗难度大、不良反应多、治疗费用高等特点致使患者治疗依从性差、治疗效果不佳 [3] [4] [5] 。相关研究表明,MDR-TB治疗成功率仅50%~70%左右 [6] [7] [8] [9] [10] 。耐药结核病的防治已然成为结核病控制的难点和重点。我国作为全球MDR-TB高负担国家之一,云南省结核病流行趋势居于全国前列,耐药结核病的高传播性将使结核病流行趋势变得更为严峻。因此,探讨可能致使MDR-TB发生的危险因素,并在此基础上提出MDR-TB预防策略与措施,以预防MDR-TB的发生,是目前公共卫生事业所要关注的重点。

研究探讨了可能引起MDR-TB发生的危险因素,结果表明,既往有结核病治疗史以及有糖尿病基础的患者更容易患MDR-TB,两者是MDR-TB发生的独立危险因素。且研究进一步提示,既往有结核病治疗史的患者相对比新诊断的患者发生MDR-TB的风险增加了9倍。这一发现与既往许多研究结果相似,证明既往结核病治疗可能是MDR-TB发生最显著的危险因素 [11] [12] [13] [14] 。一项针对我国海南三亚探讨MDR-TB发生危险因素的研究结果表明,既往抗结核治疗的患者患MDR-TB的风险增加了16倍 [15] 。此外,博茨瓦纳针对139例疑似MDR-TB患者进行危险因素研究,结果发现,既往结核病治疗史是MDR-TB发生的风险因素 [16] 。可能的原因是治疗过程中未遵循联合用药、药物剂量不足难以达到最低血药浓度、缺乏治疗监督以及患者治疗依从性差,致使结核分枝杆菌发生基因突变而产生耐药性,而获得性耐药患者又将突变的耐药结核分枝杆菌传播给其密切接触者,进一步扩大了MDR-TB的传播范围 [17] 。因此,应提升医生耐药结核病诊疗水平,制定合理治疗方案,实施DOTS策略缩短治疗周期,提高结核病治疗成功率;此外,加强结核病基础知识宣传教育,提升患者对结核病认知水平,做到治疗期间定期随访复查,结合自身身体状况及时调整治疗方案也很有必要;最后,为切断耐药结核病的传播,避免普通结核进一步发展为耐药结核。

此外,已有充分证据表明,糖尿病是结核病患者感染结核分枝杆菌的重要危险因素 [18] [19] [20] [21] 。近些年来,人们通过进一步研究发现,糖尿病可能是导致MDR-TB发生的危险因素,这与本研究结果相一致 [22] [23] [24] 。具体机制目前尚不明晰,可能与糖尿病作为一种代谢性疾病,使得机体免疫系统受损,增大了结核分枝杆菌再感染的风险而发生耐药有关 [25] 。也有学者从糖尿病对抗结核药物药代动力学的改变入手解释。Kumar等 [26] 研究发现,吡嗪酰胺等一线抗结核药物的血药浓度在机体高血糖的状态影响下水平有所下降,这在很大程度上助长了耐药性的发展。此外,糖尿病患者体内的高血糖环境为结核分枝杆菌生长提供了绝佳的养分。相较于单纯结核病患者,糖尿病患者体内结核病致病菌菌量基数更大,发生耐药的几率也就有所增加。因此,定期检测血糖水平,使用胰岛素等有效制剂控制血糖水平很有必要,可以使其不致影响抗结核药物的吸收,不利结核分枝杆菌的生长,减小耐药发生几率。最后,针对糖尿病患者除了做到常规控制血糖外,还应开展耐药结核病筛查,以期早期发现科学合理治疗,避免耐药结核病的进一步传播。

然而,这项研究有一定的局限性。首先,回顾性研究的设计,增加了选择偏差的风险;第二,从电子病历系统中获得的变量数量有限,患者的文化教育程度、经济水平以及个人嗜好(吸烟、饮酒等)等无从获取,这导致我们无法知悉结核病产生耐药性的更多危险因素;第三,研究局限于MDR-TB,未涉及到其他耐药结核病,因此不能推广到所有耐药结核病患者。尽管研究存在这些局限性,但提供了关于MDR-TB患者发生耐药的危险因素相关信息,为云南省耐药结核病的控制管理提供了思路。

5. 结论

综上所述,既往结核病治疗史、合并糖尿病是MDR-TB发生耐药的独立危险因素。未来应加强对患者的服药监督管理,加大对耐药结核防治知识的宣传教育力度,提高患者对疾病认知水平,进而做到合理规范治疗,降低MDR-TB的患病率。同时,针对易感人群制定特殊防护措施,减少耐药结核病的传播。

基金项目

云南省张文宏专家工作站(202105AF150027);云南省感染性疾病(艾滋病)临床研究中心子课题——HIV感染者结核病预防性治疗队列研究(202102AA310005-014)。

NOTES

*第一作者。

#通讯作者。

参考文献

[1] World Health Organization (2021) Global Tuberculosis Report 2020. World Health Organization Document.
[2] World Health Organization (2022) Global Tuberculosis Report 2021. World Health Organization Document.
[3] Chan, E.D. and Iseman, M.D. (2008) Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Review. Current Opin-ion in Infectious Diseases, 21, 587-595.
https://doi.org/10.1097/QCO.0b013e328319bce6
[4] Xing, W., Zhang, R., Jiang, W., et al. (2021) Adherence to Multidrug Resistant Tuberculosis Treatment and Case Management in Chong-qing, China—A Mixed Method Research Study. Infection and Drug Resistance, 14, 999-1012.
https://doi.org/10.2147/IDR.S293583
[5] Dillard, L.K., Martinez, R.X., Perez, L.L., et al. (2021) Prevalence of Aminoglycoside-Induced Hearing Loss in Drug-Resistant Tuberculosis Patients: A Systematic Review. Journal of Infec-tion, 83, 27-36.
https://doi.org/10.1016/j.jinf.2021.05.010
[6] Bogale, L., Tsegaye, T., Abdulkadir, M., et al. (2021) Unfavorable Treatment Outcome and Its Predictors among Patients with Multidrug-Resistance Tuberculosis in Southern Ethiopia in 2014 to 2019: A Multi-Center Retrospective Follow-Up Study. Infection and Drug Resistance, 14, 1343-1355.
https://doi.org/10.2147/IDR.S300814
[7] Chaves-Torres, N.M., Fadul, S., Patiño, J., et al. (2021) Factors Asso-ciated with Unfavorable Treatment Outcomes in Patients with Rifampicin-Resistant Tuberculosis in Colombia 2013-2015: A Retrospective Cohort Study. PLOS ONE, 16, e0249565.
https://doi.org/10.1371/journal.pone.0249565
[8] 林志浩, 丘小燕, 马晓慧, 等. 佛山市193例耐多药肺结核患者的治疗转归及影响因素分析[J]. 实用预防医学, 2022, 29(11): 1290-1294.
[9] 潘辰慧, 张顺先, 张少言, 等. 耐多药肺结核治疗转归的影响因素分析[J]. 解放军医学杂志, 2023, 48(9): 1040-1047.
[10] 李德富, 俞玉琪, 卢曲琴, 等. 江西省耐药结核病治疗现状与抗结核药治疗费用分析[J]. 现代预防医学, 2021, 48(18): 3425-3429.
[11] Pan, Y., Yu, Y,, Lu, J., et al. (2022) Drug Resistance Pat-terns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study. Infec-tion and Drug Resistance, 15, 4137-4147.
https://doi.org/10.2147/IDR.S373125
[12] Hirama, T., Sabur, N., Derkach, P., et al. (2020) Respiratory Syncytial Virus: Risk Factors for Drug-Resistant Tuberculosis at a Referral Centre in Toronto, Ontario, Canada: 2010-2016. Can-ada Communicable Disease Report, 46, 84-92.
https://doi.org/10.14745/ccdr.v46i04a05
[13] de Dieu Longo, J., Woromogo, S.H., Tekpa, G., et al. (2023) Risk Factors for Multidrug-Resistant Tuberculosis in the Central African Republic: A Case-Control Study. Journal of Infection and Public Health, 16, 1341-1345.
https://doi.org/10.1016/j.jiph.2023.06.007
[14] Tenzin, C., Chansatitporn, N., Dendup, T., et al. (2020) Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) in Bhutan: A Nationwide Case-Control Study. PLOS ONE, 15, e0236250.
https://doi.org/10.1371/journal.pone.0236250
[15] 符婷, 黄丽菊, 杨进军, 等. 海南省三亚市158例耐多药肺结核患者危险因素的Logistic回归分析[J]. 中国热带医学, 2020, 20(8): 789-793.
[16] Tembo, B.P. and Malangu, N.G. (2019) Prevalence and Factors Associated with Multidrug/Rifampicin Resistant Tuberculosis among Suspected Drug Resistant Tuberculosis Patients in Botswana. BMC Infectious Diseases, 19, Article No. 779.
https://doi.org/10.1186/s12879-019-4375-7
[17] Loddenkemper, R., Sagebiel, D. and Brendel, A. (2002) Strategies against Multidrug-Resistant Tuberculosis. European Respiratory Journal, 20, 66s-77s.
https://doi.org/10.1183/09031936.02.00401302
[18] Antonio-Arques, V., Franch-Nadal, J., Moreno-Martinez, A., et al. (2022) Subjects with Diabetes Mellitus Are at Increased Risk for Developing Tuberculosis: A Cohort Study in an Inner-City District of Barcelona (Spain). Frontiers in Public Health, 10, Article ID: 789952.
https://doi.org/10.3389/fpubh.2022.789952
[19] Adegbite, B.R., Edoa, J.R., Abdul, J., et al. (2022) Non-Communicable Disease Co-Morbidity and Associated Factors in Tuberculosis Patients: A Cross-Sectional Study in Gabon. Eclinicalmedicine, 45, Article ID: 101316.
https://doi.org/10.1016/j.eclinm.2022.101316
[20] Noubiap, J.J., Nansseu, J.R., Nyaga, U.F., et al. (2019) Global Prevalence of Diabetes in Active Tuberculosis: A Systematic Review and Meta-Analysis of Data from 2.3 Million Pa-tients with Tuberculosis. The Lancet Global Health, 7, e448-e460.
https://doi.org/10.1016/S2214-109X(18)30487-X
[21] Adane, H.T., Howe, R.C., Wassie, L., et al. (2023) Diabe-tes Mellitus Is Associated with an Increased Risk of Unsuccessful Treatment Outcomes among Drug-Susceptible Tuber-culosis Patients in Ethiopia: A Prospective Health Facility-Based Study. Journal of Clinical Tuberculosis and Other My-cobacterial Diseases, 31, Article ID: 100368.
https://doi.org/10.1016/j.jctube.2023.100368
[22] Montes, K., Atluri, H., Tuch, H.S., et al. (2021) Risk Factors for Mortality and Multidrug Resistance in Pulmonary Tuberculosis in Guatemala: A Retrospective Analysis of Mandatory Reporting. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 25, Article ID: 100287.
https://doi.org/10.1016/j.jctube.2021.100287
[23] Habibi, M.R., Bakhtiar, A., Indiastuti, D.N., et al. (2022) Diabe-tes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019-2020. Jurnal Ilmiah Universitas Batanghari Jambi, 22, 537-543.
https://doi.org/10.33087/jiubj.v22i1.1908
[24] Iradukunda, A., Ndayishimiye, G.P., Sinarinzi, D., et al. (2021) Key Factors Influencing Multidrug-Resistant Tuberculosis in Patients under Anti-Tuberculosis Treatment in Two Centres in Burundi: A Mixed Effect Modelling Study. BMC Public Health, 21, Article No. 2142.
https://doi.org/10.1186/s12889-021-12233-2
[25] Agustin, H., Massi, M.N., Djaharuddin, I., et al. (2021) Analy-sis of CD4 and CD8 Expression in Multidrug-Resistant Tuberculosis Infection with Diabetes Mellitus: An Experimental Study in Mice. Annals of Medicine and Surgery, 68, Article ID: 102596.
https://doi.org/10.1016/j.amsu.2021.102596
[26] Kumar, A.K.H., Chandrasekaran, V., Kannan, T., et al. (2017) Anti-Tuberculosis Drug Concentrations in Tuberculosis Patients with and without Diabetes Mellitus. European Journal of Clinical Pharmacology, 73, 65-70.
https://doi.org/10.1007/s00228-016-2132-z